Navigation Links
FDA Panel Gives Blessing to New Weight-Loss Drug
Date:5/12/2012

THURSDAY, May 10 (HealthDay News) -- An advisory panel to the U.S. Food and Drug Administration on Thursday recommended approval of the weight-loss medication lorcaserin, even though concerns remain about cardiovascular side effects.

If the agency were to give the nod to the drug, lorcaserin would become the first new weight-loss pill made available to Americans in a decade. The FDA is not bound to follow the advice of its expert panels, but it typically does.

The panel of experts voted 18 to 4, with one abstention, for approval, saying the drug's benefits "outweigh the potential risks when used long term" for people battling excess weight, the Associated Press reported.

Lorcaserin has not always received such a favorable reception. According to the AP, in 2010 scientists voiced concern that the drug might come with health risks, citing tumors that had developed in animal testing involving the drug.

However, Arena Pharmaceuticals, the San Francisco-based company that makes lorcaserin, has since submitted additional data in hopes the FDA might look more favorably on the drug.

According to a review of the available research posted by FDA staff online on Tuesday, that new data suggests that lorcaserin carries only a "negligible risk" of cancer in humans, the AP said. But concerns over the potential for cardiovascular risks -- hypertension in people with diabetes, for example, or injury to heart valves -- remain.

According to the AP, lorcaserin is one of three experimental weight-loss drugs that the FDA is taking a second look at after first saying no to the medications in 2010 or early 2011 because of concerns about significant side effects.

In February, another new weight-loss drug, Qnexa, was endorsed by an FDA advisory panel. The agency is expected to make a final decision on Qnexa in July.

More information

Find out more about healthy weight loss at the U.S. Centers for Disease Control and Prevention.

-- E.J. Mundell

SOURCE: Associated Press


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. U.S. Panel Rejects Ovarian Cancer Screening
2. Panel of serum biomarkers may reduce number of lung biopsies needed
3. FDA Panel Cites Clot Risk From Contraceptive Patch
4. Panel endorses active monitoring and delay of treatment for low-risk prostate cancer
5. Expert Panel Pinpoints Environmental Culprits in Breast Cancer
6. FDA Panels to Weigh Safety of Newer Forms of the Pill
7. Panel of melanoma mutations opens door to new treatment possibilities
8. Many on Medical Guideline Panels Have Conflicts of Interest: Study
9. Panels Rejection of PSA Test Spurs Mixed Reaction From Experts
10. Osteoporosis Drugs Safety Subject of FDA Panel
11. U.S. Panel Recommends Free Coverage of Birth Control
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA Panel Gives Blessing to New Weight-Loss Drug 
(Date:10/13/2017)... , ... October 13, 2017 , ... ... and Agile Software Development, has been awarded a contract by the Center for ... Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in a ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... treating sleep apnea using cutting-edge Oventus O2Vent technology. As many as ... disorder characterized by frequent cessation in breathing. Oral appliances can offer significant relief ...
(Date:10/12/2017)... MD (PRWEB) , ... October 12, 2017 , ... The ... of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual ... – 8. , In honor of Morris F. Collen, a pioneer in the field ...
(Date:10/12/2017)... ... , ... HMP , a leader in healthcare events and education, today announced ... Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie ... competition recognizes editorial and design excellence across a range of sectors. This year’s program ...
(Date:10/12/2017)... ... ... Health Literacy Innovations (HLI), creator of the Health Literacy ... Patient Education Network (CPEN), an independent professional organization that shares best practices in ... , As CPEN’s strategic partner, HLI will help support CPEN members by sharing ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... --  Montrium , an industry leader in powerful ... Trial Master Files & Inspection Readiness Conference ( ... Services has selected eTMF Connect to ... a leading European contract research organization (CRO), will ... enable greater collaboration with sponsors, improve compliance and ...
(Date:9/23/2017)... Janssen Biotech, Inc. (Janssen) announced today that ... U.S. Food and Drug Administration (FDA) for the Biologics ... treatment of moderately to severely active rheumatoid arthritis (RA). ... needed to further evaluate the safety of sirukumab in ... "We are disappointed ...
(Date:9/22/2017)... 2017 AVACEN Medical (AVACEN) announced that its ... helping those with the widespread pain associated with fibromyalgia ... in Essex, England commented, "I ... experiencing no sleep at all, tremendous pain, with every ... recommend [the AVACEN 100] enough, how this has and ...
Breaking Medicine Technology: